Delcath Systems, Inc. (DCTH)

Market Cap	563.66M
Revenue (ttm)	53.85M
Net Income (ttm)	-14.21M
Shares Out	34.83M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	160.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	419,664
Open	17.04
Previous Close	17.06
Day's Range	15.76 - 17.04
52-Week Range	6.33 - 18.23
Beta	0.72
Analysts	Strong Buy
Price Target	24.00 (+48.29%)
Earnings Date	May 8, 2025

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1988
• Employees: 96
• Stock Exchange: NASDAQ
• Ticker Symbol: DCTH
• Website: https://www.delcath.com

Financial Performance

In 2024, Delcath Systems's revenue was $37.21 million, an increase of 1701.69% compared to the previous year's $2.07 million. Losses were -$26.39 million, -44.66% less than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $24.0, which is an increase of 48.29% from the latest price.

Price Target

$24.0

(48.29% upside)

Analyst Consensus: Strong Buy